Very recent studies hold promise to reveal the role of stromal interaction molecule 1 (STIM1) in non-storeoperated Ca 2+ entry. Here we showed that in contrast to cytoplasmic membrane redistribution as previously noted, human umbilical vein endothelial STIM1 with a T-to-C nucleotide transition resulting in an amino acid substitution of leucine by proline in the signal peptide sequence translocated to perinuclear membrane upon intracellular Ca 2+ depletion, amplified nucleoplasmic Ca 2+ signaling through ryanodine receptor-dependent pathway, and enhanced the subsequent cAMP responsive element binding protein activity, matrix metalloproteinase-2 (MMP-2) gene expression, and endothelial tube forming. The abundance of mutated STIM1 and the MMP-2 expression were higher in native human umbilical vein endothelial cells of patients with gestational hypertension than controls and were significantly correlated with blood pressure. These findings broaden our understanding about structure-function bias of STIM1 and offer unique insights into its application in nucleoplasmic Ca 2+ , MMP-2 expression, endothelial dysfunction, and pathophysiological mechanism(s) of gestational hypertension.
Introduction
The breakthrough discovery of STIM1 in Ca 2+ influx from independent groups [1, 2, 3] heavily stroked the entire field of Ca 2+ signaling [4] . Many laboratories have been focusing on this hot field to reveal the long-lasting mechanistic mystery of Ca 2+ influx [4, 5, 6] , namely, store-operated Ca 2+ entry (SOCE). As a type I single-pass transmembrane protein, STIM1 is located not only in the endoplasmic reticulum(ER) mainly [1, 2, 3] but also in the cytoplasmic membrane to some extent [3, 7, 8, 9, 10] . Upon Ca 2+ stores depletion, STIM1 translocates from the ER into dispersed, small points underneath the cytoplasmic membrane to mediate SOCE. A critical function of STIM1 constitutively resident in the cytoplasmic membrane, not translocated from ER, is suggested for the regulation of the noncapacitative, arachidonic acid-regulated Ca
2+
-selective (ARC) channels activity in several studies [8, 9, 11] . In addition, an antibody outwardly targeted to the Nterminal EF hand of STIM1 restrains both Ca 2+ release-activated Ca
(CRAC) channel activity in hematopoietic cells and SOCE in HEK293 cells, suggesting that STIM1 executes critical functions within the cytoplasmic membrane in the absence and presence of store depletion [10] . STIM1 translocation can occur independently of SOCE in other type of cells [12, 13] . STIM1 appears to be a far more general controller of Ca 2+ signaling than originally thought and holds diverse, and even totally different, patterns of action. ] C )-dependent and -independent [14, 15] . Unlike [Ca 2+ ] C signaling, the mechanism(s) underlying the regulation of [Ca 2+ ] N remains highly mysterious [14] [15] [16] [17] [18] [19] [20] [21] [22] . Several studies reported significantly altered functions of STIM1 resulted from a single point mutation(s) either naturally occurred or artificially generated [1, 3, 10, [23] [24] [25] [26] . A gene mutation(s) can thus provide a unique and valuable approach to revealing the depth of structure-function relationship for STIM1 as also for any other protein in general. This study identified a T-to-C nucleotide mutation in human umbilical vein endothelial STIM1 and reveled its novel functions and mechanism in the regulation of endothelial nucleoplasmic Ca 2+ signaling.
Materials and methods

Cell culture
The culture of human umbilical vein endothelial cells (HUVECs) from the umbilical cord of healthy or pregnancy-induced hypertension puerpera was conducted under an institutional ethics committeeapproved protocol [27, 28] , and an informed consent was obtained from each of these women.
Confocal imaging of nucleoplasmic/cytoplasmic Ca 2+ signaling
Subcellular Ca 2+ dynamics was examined on an Olympus inverted confocal microscope (1X71) using Fluo-3, the most applicable Ca 2+ dye displaying a broad dynamic scope, low degree of cellular compartmentalization, and a suitable apparent binding affinity for Ca 2+ [29] .
HUVECs were loaded with Fluo-3 AM (prepared in DMSO), for 25 min at room temperature (RT) in HEPES buffered saline (HBS) containing NaCl 137, KCl 5.4, CaCl 2 1.5, MgCl 2 1.2, HEPES 20, and glucose 15 (in mM), pH 7.40. The cells were washed thoroughly, and Fluo-3 fluorescence was measured at the wavelength N 505 nm with an excitation at the wavelength of 488 nm. The setting of confocal pinhole was to render spatial resolutions of 400 nm in the x-and y-axes and 800 nm in the zaxis. Two-dimensional images were generated by scanning once every 0.5 s at 150 nm per pixel, 512 pixels per line, and 256 lines per image. The photobleaching and potential laser injury to the cells were minimized by lowering the laser power to~1% of its maximal level (25 ] rest was assumed to be 100 nM based on our previous studies in these types of cells using Ca 2+ fluorescent ratio indicator fura-2 [27, 28] . ] C was made.
In some experiments, InsP 3 R was inhibited by intracellular loading of heparin using the established hypo-osmotic pinocytic lysis procedure [32] . Briefly, cells were incubated in M199 contain 10% polyethylene glycol 1000, 5 mg/ml heparin, and 0.5 M sucrose at RT for 5 min. Then the cells were exposed to hypo-osmotic media (6 parts M199 to 4 parts H 2 O) for 2 min before rinsing and continuous incubation in M199 for the subsequent experiments.
Immunofluorescence
The cells were washed by PBS, fixed in cold methanol at −20°C for 10 min and rinsed twice by PBS, then treated with 0.5% Triton-PBS three times each for 15 min. The cells were rinsed completely and then incubated with a blocking solution supplemented with 0.5% bovine serum albumin and 5% donkey serum in PBS for 40 min. The cells were incubated with primary antibodies against STIM1 (mouse anti-human, 1:200 dilute; Santa Cruz) and LAP2 (rabbit anti-human, 1:200 dilute; Santa Cruz) at 4°C overnight, washed with 0.2% Triton in PBS three times each for 10 min, and probed with the required tetramethylrhodamine isothiocyanate (TRITC)-conjugated secondary antibody for STIM1 (rabbit anti-mouse; Santa Cruz) and FITC-conjugated secondary antibody for LAP2 (goat anti-rabbit; Santa Cruz) for 1 h, respectively. Cells were washed three times with 0.2% Triton-PBS each for 10 min and treated with 4′6-diamidino-2-phenylindole (10 μg/ml) for 15 min, then washed again with 0.2% Triton-PBS. In some preparations, cells were incubated with 1 μg/ml DiOC6 (Invitrogen) for 10 min and then washed three times with PBS. Fluorescence images were acquired using the confocal laser scanning microscope.
Quantitative analysis of STIM1 subcellular translocation was performed by estimating the increase in TRITC fluorescence at the nuclear membrane compared to the cytoplasm with Image Pro Plus 5.0 software.
Endothelial STIM1 cloning
The primers for PCR were designed according to a human STIM1 sequence (NM_003156). The primers of sense 5′-ATGGATGTATGCGTCC GTCTTG-3′ and antisense: 5′-CTACTTCTTAAGAGGCTTCTTAAAGATT-3′ were synthesized and purified through PAGE by the GenScript Corporation. Touchdown PCR was conducted using LApro Taq polymerase (GenScrip) with the following settings: an initial 5 min denaturation at 95°C, followed by 25 cycles of 0.5 min at 94°C, 0.5 min at 60-50°C (reduced by 0.5°C for each cycle), 1 min at 72°C, and finally an extension of 5 min at 72°C. The products of PCR were separated through a 1.5% agarose gel, and the PCR products of desired size were removed from the gel, purified with the Gel Extraction Kit (GenScript), and subcloned into the pUC57 plasmid vector (GenScript) and transformed into DH5α cells (Invitrogen). The inserts were sequenced using primers specific to the vector of an automated ABI 3730xl DNA sequencer. The point mutation was originally identified and verified by sequencing in forward and reverse directions in two separate clones and further confirmed in freshly isolated HUVECs from different donors. Sequence analysis was performed using the software of Seqman from DNAstar package (Lasergene, USA). The mutation reported here has been deposited in GenBank (accession number of JX014264) and scanned against the database, and no sequence with significant relatedness to the new mutation has been identified. Sequencing on nuclear DNA of the cells did not identify the same mutation, implying the originality of the mutation at gene editing level.
Construction of endothelial STIM1-GFP
Full-length mutated and wild-type STIM1 cDNA were cloned into pLVX-AcGFP1-1 (Clontech) at BamHI/EcoRI, respectively. The successful constructions were verified by sequencing.
Translocation of GFP-tagged protein
To determine the kinetics of STIM1 perinuclear membrane translocation, the above construct of endothelial STIM1-GFP was transfected in HUVEC on coverslips using established techniques [27, 28] .
A time series of images from HUVEC was taken using the laser scanning confocal microscope system at various time periods up to 30 min after treatment. After background subtraction, the fluorescence intensities in a dotted area in the perinuclear membrane were quantified using NIH Image Software to reveal the temporal characteristics of STIM1-GFP translocation.
Assessment of STIM1 and MMP-2 mRNA levels
Total RNA isolated from treated HUVECs was subject to real-time PCR as previously described [27, 28] . One microgram of total RNA for each sample was used to generate cDNA using Superscript 1st Strand System (Takara). Each RNA/primer was gently mixed with 25 μL cDNA Synthesis Mix (Takara) and warmed for 20 min at 37°C. The mixture was heated at 85°C for 5 s and then chilled on ice to terminate the reactions. Real-time PCR were conducted using Sybgree1 Mix (Takara) and specific primers for MMP-2 and GAPDH (Invitrogen) on Rotor Gene 3000 (Corbett) with 5 s at 95°C and a 45 cycle loop: 95°C for 5 s, 54°C for 30 s and 72°C for 30 s. The standard curve for each gene was generated and used to quantify the mRNA concentration of each sample. Duplicate measurements were conducted and the MMP-2 mRNA level was normalized by GAPDH and then expressed as a fold of the corresponding control for each condition. The assessment of wild-type and mutated STIM1 mRNA abundance was performed using the amplification refractory mutation system principle [24, 33] with 30 s at 95°C and a 50 cycle loop: 95°C for 5 s, 56°C for 45 s. The specific primers and probes for wild-type and mutated STIM1 were designed using a single forward primer: AACTTGGAGCACTTTGGCTGTT, and a single TagMan probe for both the wild-type and mutation reactions: TCCCCAGAGGAG CCACAGGGCAAGAC with labeling of 5′-FAM and 3′-TAMRA (Takara). The reverse primers were TCTGGCCCTGGTGCAGGAtGA and TCTGGCCC TGGTGCAGGAtGG for the wild-type and mutated STIM1, respectively.
The 3′-ends of the reverse primers were complementary to the wildtype or mutated STIM1 cDNA sequences, and the designated "t" was an additional mismatch incorporated to enhance allelic discrimination.
Measurement of endogenous CREB activity
An ELISA-based assay was performed to measure endogenous CREB activities as before [27, 28] .
Endothelial tube formation assay
HUVECs were serum starved overnight, treated with HBS or 1 μM histamine for 60 min and then seeded into 48-well plates pre-coated with growth factor-reduced Matrigel (BD). The cells were cultured at 37°C for 12 h at 37°C, in the normal serum-containing culture medium but without addition of extra growth factors, and endothelial tube formation was visualized by phase-contrast microscopy. The tube length was measured as the mean summed length of capillary-like structures in 2 wells, per high-power fields (2.5×) per well and normalized as a percentage of HBS-treated HUVECs. Duplicate measurements for each of 6 separate experiments for each condition were performed.
Statistical analysis
Data were presented as mean ± SE. Baseline parameters were compared between two groups using paired and unpaired Student's t-test. While multiple groups are involved, one-way ANOVA followed by Holm-Sidak or Tukey test will be performed. The significant difference was considered at a level of p b 0.05.
Results
Endogenous STIM1 translocation on Ca 2+ store(s) depletion
The STIM1 immunofluorescent staining appeared predominantly within the cytoplasm, and very little was in the nucleoplasm in resting HUVEC in HBS containing 2.0 mM Ca 2+ . In this resting condition when Ca 2+ stores were full, co-staining with nuclei and ER further showed that endogenous STIM1 co-localized with ER in HUVEC ( Fig. 1A-D) . These results are completely in agreement with previous reports in other cell types [12, 34, 35, 36] . In contrast, STIM1 staining was located predominantly in the perinuclear membrane area ( Fig. 1E-I ) after a 3 min of treatment with 1 μM thapsigargin (TG) to deplete Ca 2+ stores, as compared to resting control HUVEC. In addition to nuclei identification by DAPI, nuclei were also simultaneously stained by a monoclonal antibody against lamina-associated polypeptide 2 (LAP2), a nuclear membrane protein.
In this way, we validated that endogenous STIM1 indeed translocated to perinuclear membrane area on Ca 2+ store(s) depletion. To reveal dynamics of endogenous STIM1 subcellular redistribution, STIM1 Following the direction from the dark, nuclear area to nuclear membrane (NM) as indicated by the white line with arrow, the changes of fluorescent intensity along the vertical line crossing the inner edge of nuclear membrane were quantified and shown in the dark blue, red, and purple curves, respectively. immunofluorescent staining was performed at a series of time points after TG treatment. STIM1 staining was located predominantly in the cytoplasm at 1 min after TG treatment, aggregated mainly around perinuclear membrane area at 3 min, then returned back in the cytoplasm at 10 min, translocated at perinuclear membrane area again at 30 min, and finally located in cytoplasm at 60 min ( Fig. 1E-I ). Thus, endogenous STIM1 repetitively translocates between cytoplasm and perinuclear membrane in HUVEC after Ca 2+ store(s) depletion.
To precisely determine the dynamics of endogenous STIM1 translocation, the averaged STIM1 fluorescence in the cytoplasm and along the perinuclear membrane area (for both time control and TG-treated HUVEC) was quantitatively estimated, respectively. The ratio of the perinuclear membrane/cytoplasm pixel intensities was calculated and plotted against the time points, quantitatively summarizing the characteristics of oscillatory perinuclear membrane translocation of endogenous STIM1 upon Ca 2+ store(s) depletion for each time point, respectively (56-69 individual cells from 4 separate HUVEC preparations, Fig. 1I ).
Molecular cloning of an STIM1 variant
One STIM1 variant, the 44th single base mutation of CTC → CCC that results in a predicted substitution of the 15th amino acid of Leu by Pro was originally identified and verified by sequencing in forward and reverse directions in two separate clones and further confirmed in freshly isolated HUVECs from different donors.
STIM1-GFP subcellular translocation
To individually determine and compare the translocation kinetics of wild-type (WT) and mutated endothelial STIM1, we performed live cell imaging of STIM1 using GFP as a tracer. Ca 2+ store(s) depletion stimulated a rapid translocation of mutated STIM1-GFP from the cytosol to nuclear membrane and the subsequent sliding along nuclear membrane in HUVEC ( Fig. 2A) . By contrast, translocation from cytosol to nuclear membrane was not observed in WT STIM1-GFP expressed HUVEC after Ca 2+ store(s) depletion (Fig. 2D) . The movement or translocation of STIM1-GFP from the cytoplasm to cytoplasmic membrane was noted in both mutated and wild-type STIM1-expressing HUVEC after Ca 2+ store(s) depletion. The real-time and continuous monitoring of fluorescence intensities in one dotted area in nuclear membrane revealed interval or repetitive GFP translocation after Ca 2+ store(s) depletion in HUVEC expressing mutated (Fig. 2B and 2E) , not WT STIM1-GFP (Fig. 2D and G) or in a time control HUVEC without Ca 2+ store(s) depletion ( Fig. 2C and F) .
To determine whether the translocated fluorescence was genuinely in the nuclear membrane or just closed to it, we further performed fluorescence analysis more meticulously. As shown in Fig. 3 , we analyzed the change of fluorescent intensity along the vertical line crossing the inner edge of nuclear membrane of an area before, during, and after the translocation of fluorescence. We first determined the position of the inner edge of nuclear membrane in the area before translocation (upper left): following the direction from the dark, nuclear area to nuclear membrane as indicated by the white arrow, the fluorescent intensity rose abruptly at the 40 pixel distance from the nuclear area without fluorescence (lower, dark blue curve). In the position from which the fluorescent intensity rose abruptly, the 40 pixel distance from the nuclear area was therefore determined to be the inner edge nuclear membrane. Then we analyzed the change of fluorescent intensity along the same line when translocation of fluorescence occurred (upper middle): following the direction from the dark, nuclear area to nuclear membrane as indicated by the white arrow, the fluorescent intensity rose abruptly almost exactly from the 40 pixel distance (lower, red curve). The fluorescence translocations occurring at or overlapping with the inner edge of nuclear membrane necessarily indicated that the fluorescence was at least partly IN the nuclear membrane. After the translocation of fluorescence (upper right): following the direction from the dark, nuclear area to nuclear membrane as indicated by the white arrow, the fluorescent intensity rose abruptly also from the 40 pixel distance (lower, purple curve). The above coincidence of fluorescence changes from the same position before, during, and after fluorescence translocation indicated again that the florescence was at least partly in the nuclear membrane.
STIM1 in [Ca
2+
] N signaling ] N (R2, Fig. 4A ). The second [Ca 2+ ] peak response in nucleoplasm or cytoplasm was about 100-200% of the first one (R2/R1) in the majority of HUVEC examined (~40% and 50% for [Ca 2+ ] N and [ Ca   2+ ] C , respectively, Fig. 4B ). STIM1 knockdown profoundly inhibited the second [Ca 2+ ] peak responses in nucleoplasm and cytoplasm (Fig. 4G) . Importantly, in~60% of STIM1-knockdown HUVEC, the [Ca 2+ ] N (R2/R1) was ≤ 20% (Fig. 4H) . In contrast, in only~18% of the same HUVEC, the [Ca 2+ ] C (R2/R1) was ≤20% (Fig. 4H) ] N signal (Fig. 5D-F) (Fig. S2N-P) . Additionally, no effect of WT, mutated STIM1, or CREB inhibitor on RyR expression was noted (Fig. S3) . Taken together, the above results imply that mutated STIM1-associated [Ca 2+ ] N signaling occurs possibly through a RyRs and NAADP-dependent mechanism. ] N oscillations, the former ones ceased at 30 min after stimulation, whereas the later ones continued during the experimental period (~60 min). Histamine-stimulated [Ca 2+ ] N oscillations in the period of~60 min in~55% mutated STIM1-overexpressed HUVECs, in~21-26% control, vector, wild-type STIM1-overexpressed HUVECs, vehicle, and CREB inhibitor-pretreated HUVECs, and in only~12% STIM1-knockdown HUVECs (38, 28, 19, 34, 17, 22 , and 17 cells showing [Ca 2+ ] C oscillations in response to histamine stimulation from at least 3 separate experiments, respectively). The frequency and the spike duration of the [Ca 2+ ] N oscillations were not affected by the manipulation of STIM1 expression or the treatment with KG501, the CREB inhibitor (Fig. 8H) . However, the overexpression of mutated STIM1, not wild-type STIM1, significantly increased, whereas STIM1 knockdown obviously attenuated the amplitude of histaminestimulated [Ca 2+ ] N oscillations (those lasted for~60 min, Fig. 8I , *p b 0.05). HUVECs with the above-mentioned manipulated STIM1 expressions were stimulated by 1 μM histamine in 2.0 mM extracellular Ca 2+ for 30 ( Fig. 8J ) and 60 min (Fig. 8K) , and the manipulation of STIM1 expression did not significantly affect the 30 min histamine stimulation-activated CREB activities (Fig. 8J) . The 60 min stimulation of histamine-activated CREB activities (Fig. 8K) , MMP-2 mRNA expressions (Fig. 8L) , and tube forming (Fig. 8M) were significantly augmented in mutated STIM1-overexpressed HUVECs or obviously attenuated in STIM1 knockdown or CREB inhibitor-treated HUVECs as compared to other preparations (fold of control, *p b 0.05). The mutated STIM1 mRNA and MMP-2 protein expression were significantly higher in native HUVECs isolated from the patients with gestational hypertension than control (Fig. 8N ) and correlated with systolic blood pressure (Fig. 8O ).
STIM1 in [Ca
Discussion
We found a translocation of endogenous STIM1 to nuclear membrane upon Ca 2+ store(s) depletion in endothelial cells and then identified a single point mutation in endothelial STIM1, a T-to-C transition at nucleotide 44 that resulted in a Leu → Pro substitution at position 15 in the signal peptide. Ca 2+ store(s) depletion stimulated a rapid translocation of mutated STIM1-GFP from the cytoplasm to cytoplasmic membrane and nuclear membrane and the subsequent sliding along nuclear membrane, whereas only the translocation from the cytoplasm to cytoplasmic membrane was noted in WT STIM1-GFP under the same condition, indicating that the new phenomenon of nuclear membrane amplitude and wild-type or mutated STIM1 abundance (ratio representing relative levels normalized to one donor, F-I). Ca 2+ signal were obtained from 1 μM histamine-stimulated HUVECs when 2.0 mM extracellular Ca 2+ was present (31, 30, and 50 HUVECs for the donor, respectively). translocation of endothelial STIM1 was possibly due to the amino acid substitution. To further explore whether STIM1 is localized in the nuclear membrane of native HUVECs, we also performed mass spectrometry (MS) analysis and our MS with nuclear membrane prepared from native HUVECs indicated that STIM1 was indeed among the N1700 protein(s) identified to express in the nuclear membrane of this type of cells (Supplementary Table 1 ). The successful sample preparation was confirmed by the expression of LAP2, LMNA, and NUMA1, the well-known components of nuclear membrane simultaneously detected in the same sample prepared form the native HUVECs (also in Supplementary ] N signaling reported here agrees with previous studies in several types of cells using different protocols [14, 15, 16, 17, 18, 19, 20, 21, 22] . In the overexpression of mutated, no WT STIM1 was found to increase [Ca 2+ ] C -independent [Ca 2+ ] N signal (Fig. 6) , suggesting a particular role of mutated STIM1 in [Ca 2+ ] N signaling. The significant correlation between [Ca 2+ ] N amplitude and mutated STIM1 abundance in native HUVECs from different donors (Fig. 7) provided an additional, (patho-)physiological-relevant evidence for the mutated STIM1 in regulating [Ca 2+ ] N signaling. Although these results indicate a possible role of the mutated STIM1 in the control of [Ca 2+ ] N , the involvement of the mutated STIM1 in [Ca 2+ ] C cannot be excluded in the current study since the overexpression of mutated STIM1 also augmented [Ca 2+ ] C in some extent (Fig. 6) . The mutated STIM1 is involved in [Ca 2+ ] C in a way probably different from WT STIM1 since the overexpression of WT STIM1 did not augmented [Ca 2+ ] C in low extracellular Ca 2+ (Fig. 6 ).
InsP 3 , ryanodine, and NAADP receptors have been claimed as primary candidates for releasing Ca 2+ from the nuclear envelope [16] , although nicotinic acid adenine dinucleotide phosphate and cyclic ADPribose may work through ryanodine receptors (RyRs)-dependent and -independent way [14, 15, 16, 22] . ] N signaling. It is noted that STIM1 did not alter the expression of RyRs (Fig. S3) . [Ca 2+ ] N signaling has been reported to be critical in the regulation of many downstream cellular events [14, 15, 21, 22, 39, 40] . It was found that suppression of [Ca 2+ ] N , but not [Ca 2+ ] C , inhibited epidermal growth factor-induced transactivation of Elk-1 [41] . The functional significance of STIM1-associated [Ca 2+ ] N signaling in HUVEC was explored by measuring CREB activity and gene expression of MMP-2, which has been shown to be regulated by [Ca 2+ ] N -activated CREB pathway [42, 43, 44] . Endothelial tube forming, a process critically controlled by MMP-2 [45, 46] , was also regulated by mutated STIM1 (Fig. 8) . Our results about [Ca 2+ ] N -regulated CREB activity and gene expression are in consistence with previous studies showing that [Ca 2+ ] N and [Ca 2+ ] C distinctly control gene expression and an increase in [Ca 2+ ] N controls Ca 2+ -activated gene expression mediated by CREB [42, 43, 44, 39] . MMP-2 governs fundamental functions of a variety of cells including endothelium [45, 46, 47] . The abundance of mutated STIM1 mRNA and the MMP-2 expression were found to be higher in native HUVECs isolated from the patients with gestational hypertension than controls and were significantly correlated with blood pressure (Fig. 8) , suggesting a potential importance of mutated STIM1 in the pathobiology of hypertensive disorders of pregnancy through a [Ca 2+ ] N signaling-associated MMP-2 mechanism. In support of this, the plasma MMP-2 level, not its genotype or haplotypes, was reported to link with gestational hypertension [48] .
The cause-effect relationship between mutated STIM1-altered downstream events (including CREB activity, MMP-2 expression, and endothelial tube forming) and its nuclear membrane translocation and [Ca 2+ ] N regulation would be possibly further strengthened by employing an STIM1 variant with the single mutation, however, without nuclear membrane translocation and the regulation of [Ca 2+ ] N signal, e.g., overexpressing the mutated STIM1 lacking the amino acids 233-685, which is essential for STIM1 translocation [11] .
Taken together, our results indicated that STIM1 can not only regulate cytoplasmic Ca 2+ signaling through its well-known role in extracellular Ca 2+ influx but also independently strengthen nucleoplasmic Ca 2+ signaling by orchestrating with its Leu to Pro mutant partner and subsequently enhance the cAMP responsive element binding protein activation, matrix metalloproteinase-2 gene expression, and endothelial tube forming and may be involved in the pathohysiological mechanism(s) of gestational hypertension.
